MVA-BN Brachyury TRICOM vaccine

Drug Profile

MVA-BN Brachyury TRICOM vaccine

Alternative Names: Brachyury/TRICOM; MVA-brachyury-TRICOM

Latest Information Update: 06 Nov 2015

Price : $50

At a glance

  • Originator Bavarian Nordic; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 03 Nov 2015 Bavarian Nordic plans a phase II trial for Cancer
  • 03 Nov 2015 Adverse events and immunogenicity data from a phase I study in Cancer released by Bavarian Nordic
  • 01 Jun 2014 Phase-I clinical trials in Cancer (Late-stage disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top